Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 67.53
IDRA's Cash to Debt is ranked higher than
73% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. IDRA: 67.53 )
IDRA' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 67.53

Equity to Asset 0.87
IDRA's Equity to Asset is ranked higher than
89% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. IDRA: 0.87 )
IDRA' s 10-Year Equity to Asset Range
Min: -1.57   Max: 0.94
Current: 0.87

-1.57
0.94
Interest Coverage No Debt
IDRA's Interest Coverage is ranked higher than
63% of the 577 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. IDRA: No Debt )
IDRA' s 10-Year Interest Coverage Range
Min: 5.43   Max: 9999.99
Current: No Debt

5.43
9999.99
F-Score: 2
Z-Score: 14.76
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -43860.00
IDRA's Operating margin (%) is ranked lower than
52% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. IDRA: -43860.00 )
IDRA' s 10-Year Operating margin (%) Range
Min: -48783.02   Max: 941.09
Current: -43860

-48783.02
941.09
Net-margin (%) -43752.00
IDRA's Net-margin (%) is ranked lower than
52% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. IDRA: -43752.00 )
IDRA' s 10-Year Net-margin (%) Range
Min: -44860.38   Max: 57.33
Current: -43752

-44860.38
57.33
ROE (%) -65.75
IDRA's ROE (%) is ranked higher than
64% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. IDRA: -65.75 )
IDRA' s 10-Year ROE (%) Range
Min: -302.28   Max: 194.96
Current: -65.75

-302.28
194.96
ROA (%) -59.47
IDRA's ROA (%) is ranked higher than
61% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. IDRA: -59.47 )
IDRA' s 10-Year ROA (%) Range
Min: -181.34   Max: 63.38
Current: -59.47

-181.34
63.38
ROC (Joel Greenblatt) (%) -8465.00
IDRA's ROC (Joel Greenblatt) (%) is ranked higher than
55% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. IDRA: -8465.00 )
IDRA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -11798.05   Max: 9024.79
Current: -8465

-11798.05
9024.79
Revenue Growth (%) -100.00
IDRA's Revenue Growth (%) is ranked higher than
54% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. IDRA: -100.00 )
IDRA' s 10-Year Revenue Growth (%) Range
Min: -100   Max: 112
Current: -100

-100
112
EBITDA Growth (%) -15.90
IDRA's EBITDA Growth (%) is ranked higher than
68% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. IDRA: -15.90 )
IDRA' s 10-Year EBITDA Growth (%) Range
Min: -69.8   Max: 4.8
Current: -15.9

-69.8
4.8
EPS Growth (%) -12.20
IDRA's EPS Growth (%) is ranked higher than
72% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. IDRA: -12.20 )
IDRA' s 10-Year EPS Growth (%) Range
Min: -62.7   Max: 4.6
Current: -12.2

-62.7
4.6
» IDRA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

IDRA Guru Trades in Q4 2013

Steven Cohen 10,000 sh (New)
Jim Simons Sold Out
Jean-Marie Eveillard Sold Out
» More
Q1 2014

IDRA Guru Trades in Q1 2014

Paul Tudor Jones 23,810 sh (New)
Steven Cohen Sold Out
» More
Q2 2014

IDRA Guru Trades in Q2 2014

Paul Tudor Jones 12,055 sh (-49.37%)
» More
Q3 2014

IDRA Guru Trades in Q3 2014

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with IDRA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2013-12-31 Sold Out 0.01%$1.7 - $4.2 $ 3.8960%0
Jean-Marie Eveillard 2013-09-30 Reduce -28.29%$0.71 - $2.29 $ 3.89163%1434296
Jean-Marie Eveillard 2013-06-30 New Buy$0.46 - $0.8 $ 3.89489%2000000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.90
IDRA's P/B is ranked higher than
70% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. IDRA: 6.90 )
IDRA' s 10-Year P/B Range
Min: 0.83   Max: 548
Current: 6.9

0.83
548
EV-to-EBIT -8.57
IDRA's EV-to-EBIT is ranked higher than
77% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. IDRA: -8.57 )
IDRA' s 10-Year EV-to-EBIT Range
Min: -70.2   Max: 307.9
Current: -8.57

-70.2
307.9
Current Ratio 8.81
IDRA's Current Ratio is ranked higher than
84% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. IDRA: 8.81 )
IDRA' s 10-Year Current Ratio Range
Min: 0.02   Max: 16.05
Current: 8.81

0.02
16.05
Quick Ratio 8.81
IDRA's Quick Ratio is ranked higher than
85% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. IDRA: 8.81 )
IDRA' s 10-Year Quick Ratio Range
Min: 0.02   Max: 16.05
Current: 8.81

0.02
16.05

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.50
IDRA's Price/Net Cash is ranked higher than
87% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. IDRA: 6.50 )
IDRA' s 10-Year Price/Net Cash Range
Min: 2.02   Max: 141.33
Current: 6.5

2.02
141.33
Price/Net Current Asset Value 7.20
IDRA's Price/Net Current Asset Value is ranked higher than
85% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. IDRA: 7.20 )
IDRA' s 10-Year Price/Net Current Asset Value Range
Min: 1.99   Max: 65.5
Current: 7.2

1.99
65.5
Price/Tangible Book 6.90
IDRA's Price/Tangible Book is ranked higher than
76% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. IDRA: 6.90 )
IDRA' s 10-Year Price/Tangible Book Range
Min: 1.9   Max: 413.2
Current: 6.9

1.9
413.2
Earnings Yield (Greenblatt) -11.70
IDRA's Earnings Yield (Greenblatt) is ranked higher than
65% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. IDRA: -11.70 )
IDRA' s 10-Year Earnings Yield (Greenblatt) Range
Min: -11.7   Max: 164993.3
Current: -11.7

-11.7
164993.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:HXXA.Germany,
Idera Pharmaceuticals, Inc. was incorporated in Delaware on May 25, 1989. The Company is a clinical stage biotechnology company engaged in the discovery and development of novel synthetic DNA- and RNA- based drug candidates. It is developing drug candidates that are designed to modulate immune responses mediated through Toll-like Receptors, or TLRs. The Company is also evaluating gene silencing oligonucleotides, or GSOs, which inhibit the production of disease-associated proteins by targeting RNA. TLRs are specific receptors present in immune system cells. Using a chemistry-based approach, the Company has created synthetic DNA- and RNA-based compounds that are targeted to TLRs 3, 7, 8, and 9. A TLR agonist is a compound that stimulates an immune response through the targeted TLR. A TLR antagonist is a compound that blocks activation of an immune response through the targeted TLR. Drug candidates are compounds that the Company is developing and that have not been approved for any commercial use. The Company is focusing its internal development efforts on TLR-targeted clinical candidates for autoimmune and inflammatory diseases and cancer, and on the advancement of its GSO technology platform. The Company is developing IMO-3100, an antagonist of TLR7 and TLR9, for the treatment of psoriasis. It is conducting nonclinical studies of IMO-8400 to support the submission of an Investigational New Drug Application, or IND, for IMO-8400. Its GSOs are single-stranded RNA or DNA constructs that are complementary to targeted mRNA sequences of therapeutic interest. In preclinical studies, the Company's GSOs has inhibited in vivo gene expression without requiring a delivery enhancement technology. In addition to its clinical programs in autoimmune and inflammatory diseases and in cancer, the Company has identified TLR drug candidates for applications in the treatment of infectious diseases, respiratory diseases and hematological malignancies, and TLR3 agonists for use as vaccine adjuvants. The principal competitor developing TLR-targeted compounds for autoimmune diseases is Dynavax Technologies Corporation, or Dynavax, with its collaborator, GlaxoSmithKline plc, or GlaxoSmithKline. The testing, manufacturing, labeling, advertising, promotion, export, and marketing of its products are subject to extensive regulation by governmental authorities in Europe, the United States, and elsewhere throughout the world.
» More Articles for IDRA

Headlines

Articles On GuruFocus.com
Insiders Are Buying Idera Pharmaceuticals Sep 19 2013 
Idera Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides Pipeline Update Aug 04 2009 

More From Other Websites
IDERA PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events Dec 17 2014
IDERA PHARMACEUTICALS, INC. Files SEC form 8-K/A, Other Events Dec 15 2014
Idera Announces Several Key Additions to Management Team Dec 15 2014
Idera Announces Several Key Additions to Management Team Dec 15 2014
IDERA PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events Dec 12 2014
Idera Pharmaceuticals Presents Data Supporting IMO-8400 as Novel Therapy for Genetically Defined... Dec 08 2014
Idera Pharmaceuticals Presents Data Supporting IMO-8400 as Novel Therapy for Genetically Defined... Dec 08 2014
Idera Pharmaceuticals Announces Cancer Immunotherapy Regimen With Intratumoral IMO-2055 Demonstrated... Dec 02 2014
Idera Pharmaceuticals Announces Cancer Immunotherapy Regimen With Intratumoral IMO-2055 Demonstrated... Dec 02 2014
Mid-Morning Market Update: Markets Open Higher; Cypress To Acquire Spansion In $4 Billion Deal Dec 02 2014
Idera Announces Appointment of Robert A. Doody Jr. as Vice President of Investor Relations and... Dec 02 2014
Idera Announces Appointment of Robert A. Doody Jr. as Vice President of Investor Relations and... Dec 02 2014
Idera Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference Dec 02 2014
Idera Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference Dec 02 2014
IDERA PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Dec 01 2014
Idera Pharmaceuticals Names Vincent J. Milano Chief Executive Officer Dec 01 2014
Idera Pharmaceuticals Names Vincent J. Milano Chief Executive Officer Dec 01 2014
Idera Pharmaceuticals (IDRA) Is Today's Strong On High Volume Stock Nov 28 2014
IDERA PHARMACEUTICALS, INC. Financials Nov 15 2014
Idera Pharmaceuticals to Present at the Stifel 2014 Healthcare Conference Nov 13 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK